These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 35303381)

  • 1. Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease.
    Wang Y; Abrol R; Mak JYW; Das Gupta K; Ramnath D; Karunakaran D; Fairlie DP; Sweet MJ
    FEBS J; 2023 Jun; 290(11):2805-2832. PubMed ID: 35303381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling.
    Sinnett-Smith J; Ni Y; Wang J; Ming M; Young SH; Rozengurt E
    Am J Physiol Cell Physiol; 2014 May; 306(10):C961-71. PubMed ID: 24647541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase Hdac7 supports LPS-inducible glycolysis and Il-1β production in murine macrophages via distinct mechanisms.
    Ramnath D; Das Gupta K; Wang Y; Abrol R; Curson JEB; Lim J; Reid RC; Mansell A; Blumenthal A; Karunakaran D; Fairlie DP; Sweet MJ
    J Leukoc Biol; 2022 Feb; 111(2):327-336. PubMed ID: 34811804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages.
    Shakespear MR; Hohenhaus DM; Kelly GM; Kamal NA; Gupta P; Labzin LI; Schroder K; Garceau V; Barbero S; Iyer A; Hume DA; Reid RC; Irvine KM; Fairlie DP; Sweet MJ
    J Biol Chem; 2013 Aug; 288(35):25362-25374. PubMed ID: 23853092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases as regulators of inflammation and immunity.
    Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
    Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
    Kee HJ; Kim I; Jeong MH
    Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class IIa Histone Deacetylases Drive Toll-like Receptor-Inducible Glycolysis and Macrophage Inflammatory Responses via Pyruvate Kinase M2.
    Das Gupta K; Shakespear MR; Curson JEB; Murthy AMV; Iyer A; Hodson MP; Ramnath D; Tillu VA; von Pein JB; Reid RC; Tunny K; Hohenhaus DM; Moradi SV; Kelly GM; Kobayashi T; Gunter JH; Stevenson AJ; Xu W; Luo L; Jones A; Johnston WA; Blumenthal A; Alexandrov K; Collins BM; Stow JL; Fairlie DP; Sweet MJ
    Cell Rep; 2020 Feb; 30(8):2712-2728.e8. PubMed ID: 32101747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.
    Wright LH; Menick DR
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H199-206. PubMed ID: 27208161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-sirtuin histone deacetylases in the control of cardiac aging.
    Ferguson BS; McKinsey TA
    J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
    Bai G; Wei D; Zou S; Ren K; Dubner R
    Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
    Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
    Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylases in cardiovascular and metabolic diseases.
    Bagchi RA; Weeks KL
    J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism.
    Ma C; D'Mello SR
    J Biol Chem; 2011 Feb; 286(6):4819-28. PubMed ID: 21118817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.